AcelRx Pharmaceuticals, Inc.(ACRX)

Description: AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

---

Keywords: Cancer Pain Organic Compounds Chemical Compounds Treatment Of Cancer Clinical Trial Ethers Acute Pain Piperidines Fentanyl Stage Specialty Pharmaceutical Breakthrough Pain Sufentanil Thiophenes

---

Home Page: www.acelrx.com

ACRX Technical Analysis

25821 Industrial Boulevard
Hayward, CA 94545
United States
Phone: 650 216 3500

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)